Redeye revises our forecast and fair value range in light of TH1NG’s Q3’23 report. Although the top-line was slightly weaker than anticipated, a reduced cost base offset this, resulting in better-than-expected EBITDA. Business momentum remains robust, and TH1NG’s product portfolio experienced substantial growth with the IIOTE acquisition during the quarter. However, given the seasonality effects, we are cautious to extrapolate the stronger-than-expected margins and results observed in Q3’23.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

TH1NG - Targets positive result in FY 2025

© Modular Finance, source Nordic Press Releases